This site is intended for U.S. Healthcare Professionals only.

  • US Full Prescribing Information |
  • Medication Guide |
  • Indication

    Indication

    SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

    Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

SOTYKTU™ (deucravacitinib) Logo SOTYKTU™ (deucravacitinib) Logo

Study Designs

Efficacy

Safety

MOA

Dosing

Resources

MENU

CLOSE

Study Designs

Efficacy

Safety

MOA

Dosing

Resources

BMS Connect

Request a Rep

Visit Patient Site

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

See efficacy results from 2 pivotal Phase 3 trIAls1

CO-PRIMARY vs PlaceboPASI 75PASI 90SCALP

CO-PRIMARY vs Placebo

PASI 75

PASI 90

SCALP

Co-primary

Superior PASI 75 and sPGA 0/1 response rates vs placebo1-3

In POETYK PSO-1 and POETYK PSO-2, superior PASI 75 response rates vs placebo at Week 16

In POETYK PSO-1 and POETYK PSO-2, superior PASI 75 response rates vs placebo at Week 16 In POETYK PSO-1 and POETYK PSO-2, superior PASI 75 response rates vs placebo at Week 16

sPGA response of 0/1 at Week 16 vs placebo (co-primary endpoint)1-3

  • In POETYK PSO-1, 54% for SOTYKTU vs 7% for placebo, P<0.0001
  • In POETYK PSO-2, 50% for SOTYKTU vs 9% for placebo, P<0.0001

Study design1

POETYK PSO-1 (N=664) and POETYK PSO-2 (N=1020) were two, 52-week, multicenter, randomized, double-blind, placebo- and active (apremilast 30 mg twice daily)-controlled, Phase 3 studies to evaluate the safety and efficacy of SOTYKTU (6 mg once daily) in adult patients with moderate-to-severe plaque psoriasis who were eligible for systemic therapy or phototherapy. Patients had a body surface area (BSA) involvement of ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥12, and a static Physician’s Global Assessment (sPGA) ≥3 (moderate or severe).

Both studies assessed the responses at Week 16 compared with placebo for the two co-primary endpoints:

  • The proportion of patients who achieved at least a 75% improvement in PASI scores from baseline (PASI 75)
  • The proportion of patients who achieved an sPGA score of 0 (clear) or 1 (almost clear)

There were multiple ranked secondary endpoints, including:

  • The proportion of patients who achieved PASI 75 at Week 16 and Week 24 vs apremilast
  • The proportion of patients who achieved at least a 90% improvement in PASI scores from baseline (PASI 90) at Week 16 and Week 24 vs apremilast
  • The proportion of patients who achieved a scalp-specific PGA (ss-PGA) score of 0 (clear) or 1 (almost clear) at Week 16 vs placebo and vs apremilast

PASI 75

Demonstrated superior response rates vs apremilast1,3,4

In POETYK PSO-1, superior PASI 75 response rate vs apremilast at Weeks 16 and 24 (secondary endpoints)1,2

POETYK PSO-1 PASI 75 Response Rates (NRI)1,2 POETYK PSO-1 PASI 75 Response Rates (NRI)1,2
PASI 75 response rates in POETYK PSO-2 PASI 75 response rates in POETYK PSO-2

SELECT IMPORTANT SAFETY INFORMATION:

CONTRAINDICATIONS
SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU.

Please see additional Important Safety Information below.

Maintenance of response1

PASI 75 responders at Week 24 who maintained response at Week 521

POETYK PSO-1 PASI 75 MAINTENANCE IN PATIENTS TAKING SOTYKTU (NRI)1

82% of patients who achieved PASI 75 at week 24 maintained it through Year 1 82% of patients who achieved PASI 75 at week 24 maintained it through Year 1
  • In POETYK PSO-1, 69% of patients taking SOTYKTU (n=330) achieved PASI 75 at Week 241

    • PASI 75 maintenance rate in POETYK PSO-21

  • In POETYK PSO-2, 58% of patients taking SOTYKTU (n=511) achieved PASI 75 at Week 24
  • In POETYK PSO-2, to evaluate maintenance and durability of response, patients who were originally randomized to SOTYKTU and were PASI 75 responders at Week 24 were re-randomized to either continue treatment on SOTYKTU or be withdrawn from therapy (ie, receive placebo)
  • At Week 52, 80% (n=119/148) of patients who continued on SOTYKTU maintained PASI 75 compared to 31% (n=47/150) of patients who were withdrawn from SOTYKTU

NRI=non-responder imputation; PASI=Psoriasis Area and Severity Index; PASI 75=75% improvement from baseline in PASI score.

Study design1

POETYK PSO-1 (N=664) and POETYK PSO-2 (N=1020) were two, 52-week, multicenter, randomized, double-blind, placebo- and active (apremilast 30 mg twice daily)-controlled, Phase 3 studies to evaluate the safety and efficacy of SOTYKTU (6 mg once daily) in adult patients with moderate-to-severe plaque psoriasis who were eligible for systemic therapy or phototherapy. Patients had a body surface area (BSA) involvement of ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥12, and a static Physician’s Global Assessment (sPGA) ≥3 (moderate or severe).

Both studies assessed the responses at Week 16 compared with placebo for the two co-primary endpoints:

  • The proportion of patients who achieved at least a 75% improvement in PASI scores from baseline (PASI 75)
  • The proportion of patients who achieved an sPGA score of 0 (clear) or 1 (almost clear)

There were multiple ranked secondary endpoints, including:

  • The proportion of patients who achieved PASI 75 at Week 16 and Week 24 vs apremilast
  • The proportion of patients who achieved at least a 90% improvement in PASI scores from baseline (PASI 90) at Week 16 and Week 24 vs apremilast
  • The proportion of patients who achieved a scalp-specific PGA (ss-PGA) score of 0 (clear) or 1 (almost clear) at Week 16 vs placebo and vs apremilast

PASI 90

Superior PASI 90 response rates vs apremilast1,2,4,5

In POETYK PSO-1, nearly twice the PASI 90 response rate with SOTYKTU vs apremilast at Week 24 (secondary endpoint)1,2

POETYK PSO-1 PASI 90 Response Rates (NRI)1* POETYK PSO-1 PASI 90 Response Rates (NRI)1*

Superior PASI 90 response rates vs apremilast at Week 16 and Week 24 (secondary endpoints) were also seen in POETYK PSO-21,4

PASI 90 at Week 16 and Week 24 were secondary endpoints PASI 90 at Week 16 and Week 24 were secondary endpoints

SELECT IMPORTANT SAFETY INFORMATION:

Hypersensitivity: Hypersensitivity reactions such as angioedema have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue SOTYKTU.

Please see additional Important Safety Information below.

POETYK PSO-1 PASI 90 maintenance (NRI)1

PASI 90 responders at Week 24 who maintained response at Week 521

74% of patients on SOTYKTU who achieved PASI 90 at Year 1 74% of patients on SOTYKTU who achieved PASI 90 at Year 1
  • In POETYK PSO-1, 42% of patients taking SOTYKTU (n=330) achieved PASI 90 at Week 241

Study design1

POETYK PSO-1 (N=664) and POETYK PSO-2 (N=1020) were two, 52-week, multicenter, randomized, double-blind, placebo- and active (apremilast 30 mg twice daily)-controlled, Phase 3 studies to evaluate the safety and efficacy of SOTYKTU (6 mg once daily) in adult patients with moderate-to-severe plaque psoriasis who were eligible for systemic therapy or phototherapy. Patients had a body surface area (BSA) involvement of ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥12, and a static Physician’s Global Assessment (sPGA) ≥3 (moderate or severe).

Both studies assessed the responses at Week 16 compared with placebo for the two co-primary endpoints:

  • The proportion of patients who achieved at least a 75% improvement in PASI scores from baseline (PASI 75)
  • The proportion of patients who achieved an sPGA score of 0 (clear) or 1 (almost clear)

There were multiple ranked secondary endpoints, including:

  • The proportion of patients who achieved PASI 75 at Week 16 and Week 24 vs apremilast
  • The proportion of patients who achieved at least a 90% improvement in PASI scores from baseline (PASI 90) at Week 16 and Week 24 vs apremilast
  • The proportion of patients who achieved a scalp-specific PGA (ss-PGA) score of 0 (clear) or 1 (almost clear) at Week 16 vs placebo and vs apremilast

Scalp

Superior scalp response ss-PGA 0/1 at Week 16 vs apremilast1,3,5

In POETYK PSO-1, a greater proportion of patients achieved clear or almost clear scalp at Week 16 (secondary endpoint)1,5

POETYK PSO-1 SS-PGA 0/1 Response Rates (NRI)2* POETYK PSO-1 SS-PGA 0/1 Response Rates (NRI)2*

  • ss-PGA 0/1 at Week 16 was a secondary endpoint1
  • In POETYK PSO-1, ss-PGA 0/1 at Week 16 was 17% for placebo (n=121)1,5

ss-PGA 0/1 response rates in POETYK PSO-2 (secondary endpoints)1,3

  • In POETYK PSO-2, ss-PGA 0/1 response at Week 16 was 60% for SOTYKTU (n=305), 37% for apremilast (n=166), and 17% for placebo (n=173); P<0.0001 for both

*Include only subjects with baseline ss-PGA score of ≥3.

†P<0.0001 vs apremilast.5

‡P<0.0001 vs placebo.5

BID=twice daily; NRI=non-responder imputation; ss-PGA 0/1=scalp-specific Physician’s Global Assessment, patients achieving clear (0) or almost clear (1) skin; QD=once daily.

Study design1

POETYK PSO-1 (N=664) and POETYK PSO-2 (N=1020) were two, 52-week, multicenter, randomized, double-blind, placebo- and active (apremilast 30 mg twice daily)-controlled, Phase 3 studies to evaluate the safety and efficacy of SOTYKTU (6 mg once daily) in adult patients with moderate-to-severe plaque psoriasis who were eligible for systemic therapy or phototherapy. Patients had a body surface area (BSA) involvement of ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥12, and a static Physician’s Global Assessment (sPGA) ≥3 (moderate or severe).

Both studies assessed the responses at Week 16 compared with placebo for the two co-primary endpoints:

  • The proportion of patients who achieved at least a 75% improvement in PASI scores from baseline (PASI 75)
  • The proportion of patients who achieved an sPGA score of 0 (clear) or 1 (almost clear)

There were multiple ranked secondary endpoints, including:

  • The proportion of patients who achieved PASI 75 at Week 16 and Week 24 vs apremilast
  • The proportion of patients who achieved at least a 90% improvement in PASI scores from baseline (PASI 90) at Week 16 and Week 24 vs apremilast
  • The proportion of patients who achieved a scalp-specific PGA (ss-PGA) score of 0 (clear) or 1 (almost clear) at Week 16 vs placebo and vs apremilast

SELECT IMPORTANT SAFETY INFORMATION:

Infections: SOTYKTU may increase the risk of infections. Serious infections have been reported in patients with psoriasis who received SOTYKTU. The most common serious infections reported with SOTYKTU included pneumonia and COVID-19. Avoid use of SOTYKTU in patients with an active or serious infection. Consider the risks and benefits of treatment prior to initiating SOTYKTU in patients:

  • with chronic or recurrent infection
  • who have been exposed to tuberculosis
  • with a history of a serious or an opportunistic infection
  • with underlying conditions that may predispose them to infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment. A patient who develops a new infection during treatment should undergo prompt and complete diagnostic testing, have appropriate antimicrobial therapy initiated and be closely monitored. Interrupt SOTYKTU if a patient develops a serious infection. Do not resume SOTYKTU until the infection resolves or is adequately treated.

Viral Reactivation

Herpes virus reactivation (e.g., herpes zoster, herpes simplex) was reported in clinical trials with SOTYKTU. Through Week 16, herpes simplex infections were reported in 17 patients (6.8 per 100 patient-years) treated with SOTYKTU, and 1 patient (0.8 per 100 patient-years) treated with placebo. Multidermatomal herpes zoster was reported in an immunocompetent patient. During PSO-1, PSO-2, and the open-label extension trial, the majority of patients who reported events of herpes zoster while receiving SOTYKTU were under 50 years of age. The impact of SOTYKTU on chronic viral hepatitis reactivation is unknown. Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting and during therapy with SOTYKTU. If signs of reactivation occur, consult a hepatitis specialist. SOTYKTU is not recommended for use in patients with active hepatitis B or hepatitis C.

Please see additional Important Safety Information below

See study designs
See safety

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions such as angioedema have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue SOTYKTU.

Infections: SOTYKTU may increase the risk of infections. Serious infections have been reported in patients with psoriasis who received SOTYKTU. The most common serious infections reported with SOTYKTU included pneumonia and COVID-19. Avoid use of SOTYKTU in patients with an active or serious infection. Consider the risks and benefits of treatment prior to initiating SOTYKTU in patients:

  • with chronic or recurrent infection
  • who have been exposed to tuberculosis
  • with a history of a serious or an opportunistic infection
  • with underlying conditions that may predispose them to infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment. A patient who develops a new infection during treatment should undergo prompt and complete diagnostic testing, have appropriate antimicrobial therapy initiated and be closely monitored. Interrupt SOTYKTU if a patient develops a serious infection. Do not resume SOTYKTU until the infection resolves or is adequately treated.

Viral Reactivation

Herpes virus reactivation (e.g., herpes zoster, herpes simplex) was reported in clinical trials with SOTYKTU. Through Week 16, herpes simplex infections were reported in 17 patients (6.8 per 100 patient-years) treated with SOTYKTU, and 1 patient (0.8 per 100 patient-years) treated with placebo. Multidermatomal herpes zoster was reported in an immunocompetent patient. During PSO-1, PSO-2, and the open-label extension trial, the majority of patients who reported events of herpes zoster while receiving SOTYKTU were under 50 years of age. The impact of SOTYKTU on chronic viral hepatitis reactivation is unknown. Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting and during therapy with SOTYKTU. If signs of reactivation occur, consult a hepatitis specialist. SOTYKTU is not recommended for use in patients with active hepatitis B or hepatitis C.

Tuberculosis (TB): In clinical trials, of 4 patients with latent TB who were treated with SOTYKTU and received appropriate TB prophylaxis, no patients developed active TB (during the mean follow-up of 34 weeks). One patient, who did not have latent TB, developed active TB after receiving 54 weeks of SOTYKTU. Evaluate patients for latent and active TB infection prior to initiating treatment with SOTYKTU. Do not administer SOTYKTU to patients with active TB. Initiate treatment of latent TB prior to administering SOTYKTU. Consider anti-TB therapy prior to initiation of SOTYKTU in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during treatment.

Malignancy including Lymphomas: Malignancies, including lymphomas, were observed in clinical trials with SOTYKTU. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with SOTYKTU, particularly in patients with a known malignancy (other than a successfully treated non-melanoma skin cancer) and patients who develop a malignancy when on treatment with SOTYKTU.

Rhabdomyolysis and Elevated CPK: Treatment with SOTYKTU was associated with an increased incidence of asymptomatic creatine phosphokinase (CPK) elevation and rhabdomyolysis compared to placebo. Discontinue SOTYKTU if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Instruct patients to promptly report unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.

Laboratory Abnormalities: Treatment with SOTYKTU was associated with increases in triglyceride levels. Periodically evaluate serum triglycerides according to clinical guidelines during treatment. SOTYKTU treatment was associated with an increase in the incidence of liver enzyme elevation compared to placebo. Evaluate liver enzymes at baseline and thereafter in patients with known or suspected liver disease according to routine management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt SOTYKTU until a diagnosis of liver injury is excluded.

Immunizations: Prior to initiating therapy with SOTYKTU, consider completion of all age-appropriate immunizations according to current immunization guidelines including prophylactic herpes zoster vaccination. Avoid use of live vaccines in patients treated with SOTYKTU. The response to live or non-live vaccines has not been evaluated.

Potential Risks Related to JAK Inhibition: It is not known whether tyrosine kinase 2 (TYK2) inhibition may be associated with the observed or potential adverse reactions of Janus Kinase (JAK) inhibition. In a large, randomized, postmarketing safety trial of a JAK inhibitor in rheumatoid arthritis (RA), patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. SOTYKTU is not approved for use in RA.

ADVERSE REACTIONS

Most common adverse reactions (≥1% of patients on SOTYKTU and more frequently than with placebo) include upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis and acne.

SPECIFIC POPULATIONS

Pregnancy: Available data from case reports on SOTYKTU use during pregnancy are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Report pregnancies to the Bristol-Myers Squibb Company’s Adverse Event reporting line at 1-800-721-5072.

Lactation: There are no data on the presence of SOTYKTU in human milk, the effects on the breastfed infant, or the effects on milk production. SOTYKTU is present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SOTYKTU and any potential adverse effects on the breastfed infant from SOTYKTU or from the underlying maternal condition.

Hepatic Impairment: SOTYKTU is not recommended for use in patients with severe hepatic impairment.

SOTYKTU is available in 6 mg tablets.

INDICATION

SOTYKTU™ (deucravacitinib) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Limitations of Use:

SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

Please see U.S. Full Prescribing Information, including Medication Guide, for SOTYKTU.

References:

1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

2. Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors. Dermatol Ther (Heidelb). 2021:11(5);1763-1776.

References:

1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

2. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial [published online ahead of print, 2022 Jul 9]. J Am Acad Dermatol. 2022; https://doi.org/10.1016/j.jaad.2022.07.002.

3. Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2022;S0190-9622(22)02643-3. doi: 10.1016/j.jaad.2022.08.061

4. Warren RB, Sofen H, Imafuku S, et al. Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. Presented at: European Academy of Dermatology and Venereology (EADV) Spring Symposium; May 12-May 14, 2022; Ljubljana, Slovenia.

5. Warren RB, Armstrong A, Imafuku S, et al. Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy analysis by prior treatment in the phase 3 POETYK PSO-1 and POETYK PSO-2 trials. Oral presentation at: European Academy of Dermatology and Venereology (EADV) 30th Congress; September 29-October 2, 2021; Virtual Meeting.

6. Gooderman M, Kircik L, Spelman L, et al. Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy by prespecified baseline demographics in the phase 3 POETYK PSO-1 and POETYK PSO-2 trials. Presented at: European Academy of Dermatology and Venereology (EADV) 30th Congress; September 29-October 2, 2021; Virtual Meeting.

References:

1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

2. Data on file. BMS-REF-DEU-0020. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

3. Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2022;S0190-9622(22)02643-3. doi: 10.1016/j.jaad.2022.08.061

4. Data on file. BMS-REF-DEU-0021. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

5. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial [published online ahead of print, 2022 Jul 9]. J Am Acad Dermatol. 2022; https://doi.org/10.1016/j.jaad.2022.07.002.

References:

1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

2. Armstrong A, Gooderham M, Warren RB, et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the POETYK PSO-1 study. Oral presentation at: American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX); April 23-25, 2021; Virtual Meeting.

3. Warren RB, Sofen H, lmafuku S, et al. Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. Presented at: European Academy of Dermatology and Venereology (EADV) Spring Symposium; May 12-May 14, 2022; Ljubljana, Slovenia.

References:

1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

2. Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors. Dermatol Ther (Heidelb). 2021;11(5):1763-1776.

3. Di Cesare A, Di Meglio P. Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339-1350.

Reference:

1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU
logo
are trademarks of Bristol-Myers Squibb Company.

© 2023 Bristol-Myers Squibb Company.

Otezla is a registered trademark of Amgen Inc

1787-US-2300121 02/23

1787-US-2200110 09/22

Legal Notice|Privacy Policy|Sitemap
Bristol Myers Squibb™ Logo

SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU
logo
are trademarks of Bristol-Myers Squibb Company.

© 2023 Bristol-Myers Squibb Company.

Otezla is a registered trademark of Amgen Inc

1787-US-2300121 02/23

1787-US-2200110 09/22

Legal Notice|Privacy Policy|Sitemap
Bristol Myers Squibb™ Logo

SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU
logo
are trademarks of Bristol-Myers Squibb Company.

© 2023 Bristol-Myers Squibb Company.

Otezla is a registered trademark of Amgen Inc

1787-US-2300121 02/23

1787-US-2200110 09/22

Legal Notice|Privacy Policy|Sitemap